Pharmaceutical

Variant Bio and Novo Nordisk to identify targets for metabolic disease treatment

Variant has entered a multi-year research partnership with Novo Nordisk to identify new targets to treat metabolic conditions.

Jan 8, 2025 - 06:00
Variant Bio and Novo Nordisk to identify targets for metabolic disease treatment
Variant has entered a multi-year research partnership with Novo Nordisk to identify new targets to treat metabolic conditions.
Read the original article

Tags:

Previous Article

Acelyrin stock plunges after positive Phase II data readout in thyroid eye disease

Next Article

Candid Therapeutics signs $925m T cell engager deal with WuXi Biologics

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Exscientia acquires oral CDK7 inhibitor for $20m, plans breast cancer trial

Exscientia acquires oral CDK7 inhibitor for $20m, plans...

Jul 20, 2024

STAT+: Pharmalittle: FDA approves BioMarin gene therapy for hemophilia A; former Pfizer worker charged with insider trading

STAT+: Pharmalittle: FDA approves BioMarin gene therapy...

Jun 30, 2023

US Justice Dept cracks down on healthcare fraud schemes linked to $2.75bn loss

US Justice Dept cracks down on healthcare fraud schemes...

Jun 30, 2024